Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Number of holders
-
48
-
Total 13F principal, excl. options
-
443M
-
Principal change
-
+8.45M
-
Total reported value, excl. options
-
$361M
-
Value change
-
+$7.51M
-
Number of buys
-
25
-
Number of sells
-
-13
-
Price
-
$0.81
Significant Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q1 2020
51 filings reported holding 45845PAA6 - INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q1 2020.
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 has 48 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $443M of principal
.
Largest 10 bondholders include WOLVERINE ASSET MANAGEMENT LLC ($68.9M of principal), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) ($57.8M of principal), UBS ASSET MANAGEMENT AMERICAS INC ($52.5M of principal), Allianz Asset Management GmbH ($36.4M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($36.1M of principal), DeepCurrents Investment Group LLC ($22.9M of principal), Graham Capital Management, L.P. ($18M of principal), MACKAY SHIELDS LLC ($17.8M of principal), MORGAN STANLEY ($15.3M of principal), and STATE STREET CORP ($13.5M of principal).
This table shows the top 48 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.